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This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing 
Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess 
alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage to 
families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty 
escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost. 
The rising prevalence of overweight and obesity, affecting more than 60% of adults in the UK, is leading to an 
increasing liver disease burden. Favourable responses by industry to the UK Government’s soft drinks industry levy 
have been seen, but the government cannot continue to ignore the number of adults being affected by diabetes, 
hypertension, and liver disease. New direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection 
have reduced mortality and the number of patients requiring liver transplantation, but more screening campaigns are 
needed for identification of infected people in high-risk migrant communities, prisons, and addiction centres. 
Provision of care continues to be worst in regions with the greatest socioeconomic deprivation, and deficiencies exist 
in training programmes in hepatology for specialist registrars. Firm guidance is needed for primary care on the use of 
liver blood tests in detection of early disease and the need for specialist referral. This report also brings together all the 
evidence on costs to the National Health Service and wider society, in addition to the loss of tax revenue, with alcohol 
misuse in England and Wales costing £21 billion a year (possibly up to £52 billion) and obesity costing £27 billion a 
year (treasury estimates are as high as £46 billion). Voluntary restraints by the food and drinks industry have had little 
effect on disease burden, and concerted regulatory and fiscal action by the UK Government is essential if the scale of 
the medical problem, with an estimated 63 000 preventable deaths over the next 5 years, is to be addressed.
Introduction
This fourth report of the Lancet Commission1 on Liver 
Disease in the UK provides up-to-date evidence on the 
harm being done to the nation’s health by excess alcohol 
consumption, obesity, and viral hepatitis and the 
continuing failure to introduce effective measures of 
control.2,3 Lifestyle issues, as well as smoking, have a 
major part in exacerbating poor health with age and have 
been implicated in 30% of dementia cases.4 Public Health 
England’s 2nd Atlas of Variation in NHS Diagnostic Services 
in England5 shows that the previous steady increase in 
overall life expectancy has stalled and that the gap between 
healthy and overall life expectancy is now 16·1 years for 
men and 19·0 years for women. With 10 million adults 
regularly drinking more than 14 units of alcohol each 
week—the upper limit of safe drinking for men set by the 
Chief Medical Officer6—the extent of the resulting 
morbidity and mortality is not surprising, particularly 
with the added effects of obesity and smoking, which 
frequently occur together with high alcohol consumption. 
The Atlas5 also describes the poor provision of health 
services, including deficiencies in provision of diagnostic 
tests for liver disease, in certain regions of the country, 
which occurs alongside poverty and social inequality.
An important initiative of the Commission in 2017 
has been to bring together costs resulting from alcohol, 
obesity, and viral hepatitis infection and the escalation 
of health-care costs that is anticipated on the basis of 
current trends. In their report,7 the Foundation for 
Liver Research predict that the National Health Service 
(NHS) will incur £17 billion in costs related to alcohol 
misuse over the next 5 years. Failure to take action on 
adult obesity alone could result in an additional 
£1·9–2·0 billion in costs each year.
Briefly mentioned in this report, but of considerable 
relevance to the Commission’s recommendations, are 
the sustainability and trans formation plans (STPs) of 
NHS England and the development of accountable 
care systems. Only six of the 44 provisional STP sites 
have plans that mention liver disease specifically, 
although some do mention action on alcohol. How 
closely these new arrangements reflect Public Health 
England’s best practice guidance8 will need careful 
examination.
Recommendation 1: improving expertise and 
facilities in primary care to strengthen detection 
of early disease and its treatment, and screening 
of high-risk patients in the community 
(metrics 1.1–1.5)
The Royal College of General Practitioners (RCGP) 
Research and Surveillance Centre has access to anony mised 
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data from more than 2 million primary care clinical 
records.9 The figures for the past year are alarming: 
of 1 595 450 adult patients in the RCGP Research and 
Surveillance Centre database of primary care clinical 
records, only 421 785 (26·44%) had body-mass index (BMI) 
readings, 281 309 (17·63%) had records of alcohol 
consumption, and 48 880 (3·06%) had received an alcohol 
use disorders identification test (table 1). Additionally, only 
50 (<0·001%) people—all injecting drugs—were assessed 
for hepatitis C virus (HCV) infection status in the past 
12 months.
The number of patients diagnosed with non-alcoholic 
fatty liver disease (NAFLD) and the number of people 
who inject drugs who have chronic HCV infection are 
considerably lower than the known prevalence of these 
conditions. Despite pressures on the time of general 
practitioners (GPs), accurate recording of liver disease 
data is vital if three of the five recommendations relating 
to primary care in the National Institute for Health and 
Care Excellence (NICE) quality standards on liver disease 
are to be implemented: provision of advice on physical 
activity, diet, and alcohol to people with NAFLD; regular 
testing for advanced liver fibrosis in patients with NAFLD; 
and non-invasive testing of patients with risk factors 
for cirrhosis.10
A comprehensive list of recommended Read codes 
that cover investigations for liver diseases in primary 
care was published when the British Liver Trust, RCGP 
Clinical Priority Programme launched a comprehensive 
web-based liver disease toolkit in September, 2017.11 
However, in April, 2018, there will be a move away from 
Read codes to a different clinical  coding system, the 
Systematized Nomenclature of Medicine—Clinical 
Terms,12 which in familiarisation will represent a 
considerable demand on GP time.
Metric 1.6 in the previous report3 is discussed in 
Recommendation 4.
Recommendation 2: establishment of acute 
liver services in district general hospitals linked 
with 30 regional specialist centres for more 
complex investigations and treatment, and 
increased provision of medical and nursing 
training in hepatology (metrics 2.1–2.6)
Follow-up metric data on provision of liver services in 
hospitals will not be available until the next survey of 
hospitals is done in 2018. Information is available in the 
STPs about possible hospital reconfigurations and how 
these will link to the recommended regional centres for 
specialist liver work and the operational delivery 
networks set up to deliver the anti-HCV drugs.
After a pilot study, the Royal College of Physicians 
officially launched its new exemplar liver accreditation 
programme—Improving Quality in Liver Services13—
with access to a new online tool and up-to-date guidance 
on improving standards of hospital care.
Hepatology training and capacity
The biannual surveys done by the trainees section 
of the British Society of Gastroenterology (BSG) have 
consistently reported low levels of confidence in the 
management of certain aspects and conditions within 
hepatology, even among senior trainees. A common 
theme is low confidence in management of outpatient 
hepatology, particularly viral hepatitis, autoimmune liver 
disease, and liver transplantations (timing of referral and 
indications). This finding is concerning given the 
shortage of consultant hepatologists in district general 
hospitals,1–3 particularly considering that up to 30% of 
trainees have reported a desire to sub-specialise in 
hepatology and an additional 15% have considered such a 
career move. The main barriers to pursuing training 
were a scarcity of local training opportunities and 
difficulties in changing regions to obtain hepa tology 
training.
At present, all trainees in gastroenterology are expected 
to receive 6 months of training in a level 2 or level 3 unit. 
A level 2 unit has two or more whole-time-equivalent 
consultant hepatologists, out-of-hours endos copy, 
specialist treatments such as transjugular intrahepatic 
porto-systemic shunts, hepatocellular carcinoma multi-
disciplinary meetings, liver histopathology, dedicated 
liver clinics, and a specialist nurse team. In addition to 
these features, level 3 units have a liver transplantation 
programme. When senior trainees were asked, as part of 
the BSG Trainees Survey 2014,14 to provide information 
about duration of training in levels 1, 2, and 3 hepatology, 
less than 50% had gained 6 months or more experience 
in level 2 hepatology and less than 40% had gained 
6 months or more experience in level 3 training 
(figure 1). Furthermore, the deanery training programme 
directors reported that 47 units were providing level 2 
training in 2015–16, whereas the UK Survey of Liver 
Services done in 2015–16 identified only 19 units;3 thus, 
fewer trainees than expected are receiving adequate level 
Number of patients
Diagnosis of non-alcoholic fatty liver disease 15 984 (1·00%)
Body-mass index recorded
In past 12 months 421 785 (26·44%)
In past 5 years 932 618 (58·45%)
Patient’s alcohol units recorded
In past 12 months 281 309 (17·63%)
In past 5 years 723 279 (45·33%)
Received alcohol use disorders identification test
In past 12 months 48 880 (3·06%)
In past 5 years 164 743 (10·33%)
Assessed for hepatitis C virus infection status 
In past 12 months 50 (<0·001%)
In past 5 years 118 (0·01%)
Data are n (%). 
Table 1: Royal College of General Practitioners Research and Surveillance 
Centre data9 on primary care activity for 1 595 450 patients
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2 training. To make up for these deficiencies, the 
Commission1–3 recommended that trainees spend a 
period of 6 months in an enhanced level 1 unit, which 
has some level 2 facilities. A review of training capacity 
showed that some training rotations, namely London 
North East and North East England, do not have 
sufficient capa city for enhanced level 1 training, and 
seven training rotations are unable to accommodate 
enough trainees for level 2 and level 3 training.
New metric for primary hepatocellular carcinoma
Figure 2 shows the considerable variation in mortality 
(2·6 times) of primary hepatocellular carcinoma between 
different regions of the country (mapped by STPs), 
a reflection of the increased burden of disease, the scarcity 
of specialist services in the more deprived areas, and 
the general failure to institute surveillance programmes 
for patients with cirrhosis. The steady increase in 
frequency of primary hepatocellular carcinoma reflects 
continuation of the two most frequent causes of the 
disease, namely excess alcohol consumption and obesity 
(often in combination).
The proportion of people aged 15 years or older with 
hepatocellular carcinoma who are receiving treatment 
with curative intent (liver transplantation, major liver 
resection, or ablation) is alarmingly low at 15·7% 
(table 2), with considerable variation between regions.
Recommendation 3: a national review of liver 
transplantation to ensure better access for 
patients and to increase capacity (metrics 3.1–3.5)
1003 liver transplantations were done in 2016 (children 
included), which is a substantial increase from previous 
years, although still fewer than the number of new 
registrants added to the waiting list (1169 new registrants 
added to the 600 pre-existing registrants, with 72 patients 
on the waiting list dying and 168 being removed because 
of sickness). Although 95–100% of patients survive 
elective transplantation, 5 year survival rates vary 
considerably between transplantation centres. The 
introduction of normo thermic machine perfusion, which 
should decrease the proportion of potential grafts 
considered unsuitable for implantation (15% of donated 
organs in 2016–17), is strongly recommended by the 
Commission. We also recommend the intro duction of 
presumed consent in England on the basis of results in 
Wales, where a quarter of donations came from presumed 
consent during the first 12 months after its introduction, 
alongside an increase in the num ber of all transplantations.
The aim of the new national offering sequence for 
donation—which is scheduled to start in December, 2017, 
and will mean that the first offer of an organ will no 
longer be directed to the centre but to the highest-ranked 
suitable patient—is to improve equity of access and 
maximise patient benefit. The marked variation between 
centres in acceptance of donated organs is anticipated to 
also decrease.
With an almost certain increase in donor organs as a 
result of these outcome measures, the strategic review by 
NHS England to be done in 2018 will consider increasing 
capacity either within existing centres or by establishment 
of new centres, as was strongly endorsed in the 
2016 Commission report,3 with the southwest (Plymouth) 
and the northwest (Liverpool) being the most obvious 
places for consideration.
Recommendation 4: specialist paediatric services 
and continuity of care in transition arrangements 
for children with liver disease reaching adult life 
(metrics 1.6 and 4.1–4.3)
Table 3 shows data on the number of children born with 
persistent conjugated jaundice lasting longer than 14 days 
(in babies born at term) or 21 days (in babies born 
preterm) who were referred to the three national 
paediatric liver units between 2012 and 2017. Most babies 
diagnosed with extra hepatic biliary atresia were referred 
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Figure 1: Duration of training of senior trainees in levels 1, 2, and 3 hepatology
Proportion of patients
England 15·7% (1564/9977)
East Midlands 15·8% (112/710)
East of England 16·1% (167/1038)
London 15·4% (204/1323)
Northeast 11·4% (77/676)
Northwest 16·2% (270/1667)
Southeast 14·0% (188/1342)
Southwest 16·3% (173/1059)
West Midlands 17·3% (180/1043)
Yorkshire and the Humber 17·2% (193/1119)
Data are % (number of patients diagnosed/number of patients treated). Data are 
from the National Cancer Registration and Analysis Service, Public Health England.5
Table 2: Proportion of patients aged 15 years or older with 
hepatocellular carcinoma receiving treatment with curative intent 
(liver transplantation, major liver resection, or ablation) within 
6 months of diagnosis, by region (2010–14)
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before age 56 days, but the range was wide (0–242 days) 
and 56 children were seen after that time, too late for a 
benefit to be obtained from early surgery.15 This variation 
in time to referral is unacceptable, and specialist centres 
need more support in their efforts to improve early 
diagnosis.
With regard to training of physicians in continuity care 
for children with liver disease, an electronic questionnaire 
on transition arrangements for children with liver 
disease reaching adult life, prepared in collaboration 
with the British Society for Gastroenterology, and a draft 
document specifying training requirements for phy-
sicians caring for young adults have been submitted to 
the Specialist Advisory Committee for Gastroenterology.16 
No inform ation is available about existing arrangements.
Recommendation 5: measures to reduce overall 
alcohol consumption in the country 
(metrics 5.1–5.5)
Alcohol policy, consumption, and use disorders
In England, 595 131 adults with alcohol dependency are 
in need of specialist alcohol treatment. Of these, an 
estimated 173 399 have dependency of moderate severity 
and 107 979 have severe dependency. 57% of adults 
with alcohol dependency in 2014 wanted to reduce their 
alcohol consumption.17 According to the Adult Psychiatric 
Morbidity Survey in 2014,18 7·1 million (16·6%) adults in 
England were consuming alcohol at hazardous levels 
(>14 units per week) and a further 813 000 (1·9%) at 
harmful levels (>35 units per week for women and 
>50 units per week for men). Although the proportion of 
men and women who were harmful or mildly dependent 
drinkers did not change between 2000 and 2014, 
important changes were observed in different age 
groups, with a reduction in consumption seen in young 
adults aged 16–24 years (6·8% in 2000 vs 4·2% 
in 2014), although the exact reasons for this change were 
not identified.
A report19 by Public Health England on an evidence-
based alcohol policy, which was submitted to ministers 
in late 2016, confirmed the findings of previous re-
ports, most recently by the Organisation for Economic 
Co-operation and Development,20 that fiscal policy is by 
far the most cost-effective option for reduction of alcohol 
consumption, along with regulation of alcohol marketing 
to reduce exposure of children to market pressures. The 
situation in Scotland is more promising than in England, 
with the UK Supreme Court’s ruling on Nov 15, 2017, that 
Scotland can set a minimum unit price for alcohol, 
rejecting a challenge from the Scotch Whisky Association. 
The Scottish Government has indicated that minimum 
unit pricing will be implemented early in 2018. Wales is 
following a similar path, and on Oct 23, 2017, the Welsh 
Government introduced the Public Health (Minimum 
Price for Alcohol) (Wales) Bill. The comprehensive new 
alcohol strategy of the Irish Government includes 
minimum unit pricing and strict regulation of marketing, 
with a variant of the French loi Evin.21 With the Republic 
of Ireland and Wales moving forwards on the intro-
duction of minimum unit pricing, England cannot be 
too far behind.
Alcohol consumption in the UK, which peaked at 
around 5 642 000 hL (hectolitres) in 2008–09, decreased 
when the duty escalator was introduced to around 
4 843 000 hL in 2013–04, and increased again to 
5 126 000 hL in 2016–17 after the duty escalator was 
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Figure 2: Variation in mortality due to hepatocellular carcinoma in people younger than 75 years by STP (2011–15)5
Mortality standardised per 100 000 population. STP=sustainability and transformation plan. Reproduced with permission of Public Health England.
Total referrals* Extrahepatic biliary 
atresia diagnosis
Age at referral 
(days)
Referral after 
56 days of age
Birmingham Children’s 
Hospital
661† 69 49 (10–104) 15/69 (22%)
King’s College Hospital 902‡ 126 50 (0–242) 31/126 (25%)
Leeds 554 63 34 (4–126) 10/63 (16%)
Total 2117 258 45 (0–242) 56/258 (22%)
Data are n, median (range), or n/N (%). *Includes all patients referred (age <6 months), including telephone referrals, 
outpatients, and inpatients. †Underestimate for years 2012–13 and 2016–17 because of inaccurate data for telephone 
referrals. ‡Does not include telephone referrals or outpatients.
Table 3: Referral of infants (<6 months) with persistent conjugated jaundice to the three national 
paediatric liver units and diagnosis of extrahepatic biliary atresia (2012–17)
www.thelancet.com   Published online November 29, 2017   http://dx.doi.org/10.1016/S0140-6736(17)32866-0 5
Health Policy
withdrawn.22 These changes show how responsive 
population alcohol consumption is to small changes 
in taxation and further support the Commission’s 
recommendation for an increase in overall alcohol 
taxation.
Treatment access in hospital and community alcohol 
services
Ensuring access to specialist alcohol treatment in the 
community is a key element of the WHO Global 
Alcohol Strategy, which states that “individuals and 
families affected by the harmful use of alcohol should 
have access to affordable and effective prevention and 
care services”.23 One study24 of psychosocial treatment for 
alcohol dependence in the UK showed savings to the 
public sector of £5 for every £1 spent. An economic 
analysis by Public Health England also concluded that 
alcohol screening and brief interventions, together with 
alcohol care teams and alcohol assertive outreach teams 
proactively engaging with social care services, will return 
exponential savings over the cost of delivery.19
The number of people accessing specialist alcohol 
treatment in England, as recorded by the National 
Drug Treatment Monitoring System, has increased 
slightly from 107 218 in 2008–09 to 113 222 in 2015–16.25 
In Scotland, estimates of the number of people 
accessing treatment show an increase in access (from 
16 952 in 2008–09 to 28 500 in 2015–16),26 which 
coincided with an increase in annual investment in 
treatment services of £28 million. The ratio of treatment 
access to hospital admissions for alcohol dependency, 
which serves as a proxy indicator of the prevalence in 
the general population, decreased slightly from 1·56 in 
2008–09 to 1·40 in 2015–16 in England. By contrast, 
in Scotland, the ratio increased considerably from 
1·75 to 2·69 in the same period.27 These findings 
highlight the need to upgrade and fund measures for 
reducing levels of dependency and increasing treatment 
access in England.
For 2017–18, the national Commissioning for Quality 
and Innovation scheme,28 which includes an alcohol 
metric that incentivises identification of alcohol 
use disorders, was implemented in mental health 
and community trusts, with secondary care to follow 
in 2018–19. Hospital trusts will receive financial 
reimbursement when they deliver screening of 50% of 
adult inpatients, with 80% of those identified as above low 
risk receiving appropriate intervention. To support local 
planning and commis sioning, Public Health England has 
published guidance,8 which includes recommendations to 
establish or optimise alcohol care teams in district 
hospitals and assertive outreach teams, to ensure prompt 
access to treatment services for parents identified as 
harmful or dependent drinkers, and to ensure agreed 
pathways to reduce the risks to children. It is to be hoped 
that the situation in England will be improved by the 
government’s 2017 drug strategy.29
Alcohol-related mortality, years of life lost, and hospital 
admissions
Alcohol-related deaths in England and Wales decreased 
from a peak of 7312 in 2008, when the alcohol duty 
escalator was introduced, to 6999 by 2012, but increased 
to 7630 in 2016 after abolition of the alcohol duty 
escalator in 2013.30 Liver disease mortality and the 
socioeconomic deprivation index are closely associated 
(figure 3). Mortality is mainly seen in the middle-aged 
group. In 1999, liver disease surpassed lung cancer and 
breast cancer as the leading cause of years of working 
life lost, and is set to overtake ischaemic heart disease 
within 2–3 years (figure 4).31,32
Of the two official measures of alcohol-related hospital 
admissions, the broad measure includes both primary 
and secondary diagnoses and is a more accurate 
reflection of the total burden of alcohol-related harm. 
The narrow measure, introduced in 2014 to compensate 
for changes in coding, includes only primary diagnoses 
and provides a lower estimate than the broad measure.33 
In 2015–16, 1·1 million broad-measure admissions were 
recorded, representing 7% of total hospital admissions, 
an increase of 4% compared with the previous year. 
In the same period, the narrow measure increased 
by 3% to 339 000 admissions.34 The main age group for 
alcohol-related hospital admissions was 45–54 years, 
and 61% of admissions were male. Blackpool had the 
highest number of alcohol-related hospital admissions 
(3540 per 100 000 population) and Kingston upon 
Thames had the lowest (1400 per 100 000 population).
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Figure 3: Heat map showing mortality per 100 000 population attributable to alcoholic liver disease by age 
and Index of Multiple Deprivation quintile 
The highest density of deaths is indicated by dark colours. 
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Recommendation 6: promotion of healthy 
lifestyles to reduce obesity and the burden of 
NAFLD (metrics 6.1–6.5)
Prevalence of child and adult obesity
New data have been added for each of the metrics in this 
section. Figures for the number of individuals with a BMI 
of 30 kg/m² or greater in England, Wales, Scotland, and 
Northern Ireland— derived from the Health Survey for 
England35 and equivalent surveys in the other three 
countries36–38—show a trend of increasing prevalence of 
obesity in adults. The prevalence of obesity in the Welsh 
Health Survey was lower than the prevalence in the other 
surveys, which might reflect use of self-reported data 
instead of measured height and weight in that survey.39 
Comparable data on childhood obesity from across the 
UK are scarce, with Scotland and Northern Ireland using 
a different definition of obesity in their official statistics to 
that used by England and Wales.40 However, the available 
data appear to show a levelling off in the prevalence of 
childhood obesity, although the average figures probably 
conceal widening inequalities in socioeconomic 
distribution, by ethnicity, and in severity.41,42
The government’s childhood obesity plan,43 published in 
2016, instituted a soft drinks industry levy of 18 p per litre 
for drinks with an added sugar content of greater than 5 g 
per 100 mL and 24 p per litre for those with an added sugar 
content of above 8 g per 100 mL.44 Evidence of the 
effectiveness of this approach is growing,45–49 with several 
manufacturers of soft drinks starting to reformulate their 
products. The update to the UK childhood obesity plan,50 
released in August, 2017, which proposed calorie reduction 
in types of foods consumed by children, has not been 
included in a levy approach, and the absence of an obesity 
plan for adults remains a major concern.
NAFLD in secondary care 
The annual number of finished consultant episodes for 
NAFLD shows steady increases in hospital activity across 
the four nations (figure 5). There remains a paucity of 
studies defining those with NAFLD at risk of progression 
to liver disease. The increase in liver disease burden 
from NAFLD is also reflected by the number of patients 
being listed for transplantation, with NAFLD now the 
second most common indication for transplantation 
(figure 6).
Number of primary bariatric surgery operations
Around 2 million people in the UK fulfil NICE eligibility 
criteria for bariatric surgery: a BMI of 35 kg/m² or higher 
together with an obesity-associated comorbid condition 
or a BMI of 40 kg/m² or higher.51 Liver disease, 
particularly NAFLD, is often either the indication for 
bariatric surgery or a comorbid diagnosis. However, 
despite the effect iveness of the surgical procedure in 
terms of reversal of diabetes and comorbid disease with 
substantial weight loss, fewer than 6000 operations were 
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done in 2016, which was less than 0·3% of the eligible 
population. The most up-to-date data from the Health 
and Social Services Information Centre indicate an 
almost 10% decrease in the number of procedures since 
2016.52 Such marked under-provision of bariatric surgery 
is unacceptable in terms of the current obesity epidemic.
Recommendation 7: elimination of chronic HCV 
infection from the country by 2030 and a major 
reduction in the burden of disease for 
hepatitis B (metrics 7.1–7.5)
Number of HCV-infected patients treated with 
direct-acting antiviral therapies
The effectiveness, ease of use, and overall safety of new 
direct-acting antiviral drugs against HCV infection have 
enabled progress to be made in the UK towards the goal 
of elimination of this infection and reduction of the 
associated burden of liver disease. NHS England data 
show that the 22 HCV operational delivery networks 
treated 9440 cases between April, 2016, and March, 2017,53 
and plans are now in place to treat 12 500 cases in 2017–18. 
An interim analysis of sustained virological response data 
from the national programme in England, completed in 
November, 2016, found that 92·4% of patients who were 
alive 3 months after cessation of therapy had a sustained 
virological response (Foster G, unpublished). In Scotland, 
1685 patients were treated with the new direct-acting 
antiviral drugs between April, 2016, and March, 2017 
(35% with fibrosis stage 3–4; Dillon J, unpublished). 
Based on preliminary data, 742 (95%) of 781 patients 
treated with direct-acting antiviral drugs between 
April, 2016, and March, 2017, in Wales had a sustained 
virological response (Healy B, University Hospital of 
Wales, personal communication). In Northern Ireland, 
101 (96%) of 105 patients treated between March, 2015, 
and July, 2016, had a sustained virological response 
(McDougall N, unpublished).
Diagnosis of HCV and HBV infections
The number of laboratory-confirmed reports of HCV 
infection in England has been steadily increasing since 
the 1990s, and, in 2015, 11 605 individuals tested positive 
for HCV.54 Consistent with this finding, test statistics from 
23 sentinel laboratories showed an increase of 18·6% in 
the number of tests done between 2011 and 2015, although 
the proportion of positive results declined from 2·6% 
in 2011 to 1·5% in 2015.54 Surveys do not show any 
reduction in the nUmber of new HCV infections, and the 
estimated prevalence of HCV infection in people new to 
drug use was 27% in 2016 compared with 23% in 2006.55 
These figures suggest that, if the number of patients 
treated with direct-acting antiviral drugs is to be sustained, 
an increase in new diagnoses from pools of unrecognised 
infection in the country will be needed. These pools 
include drug addiction clinics with high levels of HCV 
infection, in which only around half of people who inject 
drugs are aware of their HCV antibody status, a figure that 
has remained reasonably stable over the past 6 years. 
Moreover, the proportion of people who inject drugs who 
report adequate needle or syringe provision is suboptimal, 
with only about half reporting adequate provision.25 The 
call from the WHO Global Health Sector Strategy56 to 
reduce new cases of chronic HCV infection by 30% by 2020 
and by 80% by 2030 will be a challenge for the NHS and is 
unlikely to be met.
Figures for the devolved nations are more encouraging, 
showing substantial reduction in the number of new 
diagnoses. In Scotland, the number of new cases of 
HCV antibody positivity decreased from 1815 in 2015 to 
1594 in 2016 (Dillon J, unpublished). In Wales, provisional 
data from laboratory reports showed a reduction in new 
Figure 5: Finished consultant episodes per 100 000 population in England, Wales, Scotland, and Northern 
Ireland for 1999–2016 
Data for England come from Hospital Episode Statistics,35 data for Scotland come from the SMR01 dataset 
provided by ISD Scotland,36 data for Wales come from the Patient Episode Database for Wales,37 and data for 
Northern Ireland come from the Hospital Inpatient System.38
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cases positive for HCV antibody: 531 cases were positive 
for HCV antibody in 2016 compared with 612 in 2015 
(Healy B, University Hospital of Wales, personal 
communication). In Northern Ireland, reports of new 
laboratory-confirmed antibody positivity for 2016 were 
down by 13% compared with the figure for 2015 
(McDougall N, unpublished).
No new data are available on the number of 
hepatitis B virus (HBV) infections in England since the 
data shown in the 2015 Lancet report.2 Figures for 
Scotland and Wales are also awaited. In Northern Ireland, 
101 HBV infections were reported in 2016, including 
18 new antenatal cases, compared with 91 infections in 
2015, of which 11 were new antenatal cases (McDougall 
N, unpublished). The Unlinked Anonymous Monitoring 
Survey55 showed that the prevalence of antibodies to the 
HBV core antigen (anti-HBc, a marker of past or current 
infection) in people who inject drugs across England, 
Wales, and Northern Ireland declined from 26% in 2006 
to 13% in 2015, although uptake of the HBV vaccine 
has not increased. At least 20% of people who inject 
drugs who have not been vaccinated for HBV are 
still unprotected, and, despite current patterns of 
immigration, HBV blood samples are not being tested 
routinely for hepatitis D infection.
Mortality from HCV and HBV
A 2017 report54 compiling data from different sources for 
England, Scotland, Wales, and Northern Ireland showed 
that the number of new cases of HCV-related end-stage 
liver disease or hepato cellular carcinoma remained stable 
at around 1875 per year (range 1809–1933) from 
2011 to 2015. Deaths for which HCV was mentioned on 
the death certificate increased steadily from 215 in 2005 
to 456 in 2014, but decreased in 2015, the first year in 
which new direct-acting antiviral drugs were used in 
advanced liver disease associated with HCV-related end-
stage liver disease.54 Preliminary data initially suggested 
an 11% decrease in deaths for 2015, but this figure was 
subsequently revised to 3% because of high numbers of 
late reports of HCV-related end-stage liver disease and 
hepatocellular carcinoma. The provisional figures for 
2016 suggested a further 7% decrease. The number 
of liver transplantations had also decreased, from 
122 transplantations in 2014 to 83 in 2015, which is 
further evidence that the new drugs are already having 
an effect on mortality from HCV-related end-stage liver 
disease and primary hepatocellular carcinoma. The 
WHO Global Health Sector Strategy on Viral Hepatitis 
for 2016–2156 aims to reduce HCV-related mortality by 
10% by 2020 and by 65% by 2030. Achievement of this 
target in England will be dependent on the diagnosis of 
undiagnosed infections.
Mortality from chronic HBV infection, although greatly 
reduced after the introduction of nucleoside analogues 
inhibiting viral replication, is still affected by instances of 
viral reactivation and the long-term risk of primary 
hepatocellular carcinoma. With new curative drugs for 
chronic HBV infection in the pipeline, wider screening 
procedures are needed to address the unrecognised pools 
of chronic HBV infection in the community, including 
in accident and emergency departments, prisons, and 
services for people who are homeless.
Number of infants completing a course of HBV 
vaccination
Figures for 2016–17 in England are encouraging, with 
data from the Cover of Vaccination Evaluated Rapidly 
programme57 showing that 1908 (85%) of 2245 infants 
born to HBsAg-positive mothers completed a course of 
three vaccinations within 12 months and 1549 (69%) had 
completed the full course by age 2 years. Similar data 
from Wales showed that 50 (94%) of 53 infants had 
completed a course of three vaccinations by age 
12 months.58 Universal vaccination for HBV is in place, 
and in July, 2017, it was announced that a new hexavalent 
vaccine will be introduced across the UK for babies born 
after Aug 1, 2017, providing pro tection against diphtheria, 
tetanus, pertussis, polio, Haemophilus influenzae type b 
infection, and HBV infection.
Recommendation 8: increasing awareness of 
liver disease in the general population, within 
the NHS, and, vitally, within governments; 
increasing the inclusion and involvement of 
liver patients and patient groups in new 
developments and ongoing work with national 
and local initiatives (metrics 8.1–8.4) 
Public health campaigns and patient representation
Ongoing health campaigns include the Children’s Liver 
Disease Foundation Yellow Alert,59 which aims to 
highlight the signs and symptoms of neonatal liver 
disease to prompt early diagnosis. Over the past 5 years, 
14 000 protocol packs have been distributed to health-
care professionals, with an additional 35 000 being 
downloaded from the foundation’s website. The British 
Liver Trust’s Love Your Liver campaign60 comprises an 
easy to use screen for the three preventable lifestyle 
causes of liver disease, with more than 80% of the 
98 237 screens completed over the past 3 years showing 
the presence of risks that could cause liver disease. Of 
2669 people who attended a screening event, 2126 (80%) 
were found to be at risk of liver disease, with 496 (19%) 
being referred for further tests.
Progress reports from the devolved nations
Scotland
Later this year, the Scottish Government will publish an 
update of its alcohol strategy to improve early identi-
fication of liver damage and to focus treatment services 
more effectively on those at greatest risk. A programme 
of research has been commissioned to establish the 
effect of implementing minimum unit pricing, subject to 
the decision of The Supreme Court. With about 80% of 
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the estimated number of cases of HCV infection having 
been diagnosed, bringing the remaining cases to 
treatment will involve implementation of innovative 
pathways of care, including delivery of treatment by 
community pharmacists. A pilot study (Dillon J, 
unpublished) of automated reflex testing of the causes of 
liver disease immediately on detection of abnormality in 
the index blood sample showed the process to be 
cost-effective in achieving earlier diagnosis, and this 
strategy is being implemented in the 14 regional NHS 
boards responsible for the protection and improvement 
of their population’s health and for the delivery of front-
line health-care services.
Northern Ireland
NICE guidelines on NAFLD and diagnosis of cirrhosis 
have been accepted but not fully implemented, partly due 
to the scarcity of resources for measurement of fibrosis 
by transient elastography. The regional liver unit in 
Belfast plans to expand to five hepatologists in 2018, and 
most of the nine hospitals outside Belfast now have at 
least one gastroenterologist with an interest in liver 
health. The adult liver transplantation service for 
Northern Ireland, which is based in Belfast and is in 
collaboration with King’s College Hospital, London, is 
delivering 20–24 trans plantations per head of the 
population per year, which is proportionally in line with 
the rest of the UK.
A care pathway for alcohol use disorders was launched 
by the Public Health Authority in 2017 and has been 
adopted by all five Health and Social Care Trusts in 
Northern Ireland. Additionally, plans exist to appoint 
more substance-misuse liaison nurses before the end of 
2017. A regional report on alcohol-related brain damage is 
due to be published imminently. Funding for an alcohol 
assertive outreach liaison, established in the Belfast 
Health and Social Care Trust, has not been renewed, and 
no further expansion in numbers (currently 98) of alcohol 
specialist nurses across the five trusts has been observed.
Wales
The Public Health (Wales) Bill, passed on May 17, 2017, 
commited the Welsh Government to an obesity pre vention 
strategy. After a series of round table events in the Senedd 
(National Assembly for Wales), cross-party support was 
obtained to commit to the WHO target date of 2030 for 
elimination of HCV infection. Ongoing commitment to 
enhancing alcohol-care teams has led to an increase in the 
number of alcohol liaison nurses, from 13 to 21 over the 
past 18 months, and four of six health boards now have 
an alcohol clinical lead. In response to a pilot study 
(unpublished), reflex testing of aspartate aminotrans ferase 
concentration when the alanine amino transferase con-
centration is abnormal has been identified as a clinical 
priority within the GP contract for Wales for 2017–18. A GP 
Champion of Liver Disease, supported by the National 
Strategy and with a specific remit to improve adherence to 
the British Society of Gastroenterology guidelines on 
abnormal liver function tests and the development of an 
NAFLD pathway, has been appointed to each health board 
for 2 years. Finally, funding has been set aside for a data 
officer dedicated to improving the clinical coding of liver 
disease via use of the Welsh Clinical Portal.
Conclusion
The further increase in disease burden from excess alcohol 
consumption, obesity, and viral hepatitis reported in this 
fourth annual report of the Lancet Commission1 on Liver 
Disease in the UK is unacceptable because so little is being 
done to avert it. All of the measures proposed by the 
Commission were carefully considered, in particular the 
minimum unit pricing and sugar levy, which would target 
people at most risk of serious disease and improve their 
chances of good quality of life. With the support of the 
many institutions we have brought together in our work 
this year and the activity of parliamentarians, as judged by 
the number of questions raised in the House of Commons, 
it is difficult to understand how the government cannot 
bring in the necessary regulations to alleviate the present 
level of disease burden in the UK.
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